Nanjing, Sept. 27, 2021, Zenshine Pharmaceuticals Co., Ltd. (Zenshine) announced that NMPA (National Medical Products Administration) has approved its IND application of ZX-7101A to proceed phase 1 clinical trial for the treatment of Influenza virus infection. The phase I clinical study is focused on safety, tolerability , PK and food effects of ZX-7101A tablet in healthy volunteers.
Dr. Jinfu Yang, the co-founder and President of Zenshine, said, “Influenza pandemics have caused serious illness, death and heavy burden to the society. There is an urgent need to develop a highly effective therapy to prevent and treat broad spectrum influenza viruses.
ZX-7101A is a novel PA inhibitor developed by Zenshine . It has broad-spectrum activity against influenza A, B viruses and highly lethal variants of influenza viruses. In comparison with Baloxavir, ZX-7101A showed better efficacy in animal model and improved bioavailability with minimal food effects”.
About Zenshine Pharma
Zenshine Pharma is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Our mission is to apply the best science to serve patients. Zenshine leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine commits to providing bench-side to bed-side solutions and delivering the best-in-class or first-in-class therapeutics.
